News & Updates

For young women with a pathogenic variant in BRCA1 or BRCA2, initiating hormone replacement therapy following surgical menopause does not appear to significantly increase the risk of breast cancer, with oestrogen-alone therapy even conferring protection, according to a study.

For patients with multiple myeloma who have received up to three lines of therapy, combination treatment with the bispecific antibody teclistamab plus the monoclonal antibody daratumumab yields significant improvements in progression-free survival and overall survival, according to the phase III MajesTEC-3 trial.

Risk-reducing bilateral mastectomy in patients with the BRCA pathogenic variant appears to be associated with lower overall and breast-cancer specific mortality, according to a meta-analysis.

In the treatment of patients with advanced soft-tissue sarcoma, combining anlotinib with anthracyclines and ifosfamide in the first-line setting followed by anlotinib maintenance has demonstrated promising efficacy, with acceptable toxicities, in a phase II study.

Metastasis-directed stereotactic body radiotherapy (SBRT) alone can delay the need for systemic therapy in some patients with oligometastatic cancer, with low risks of treatment-related adverse events, according to a meta-analysis.

Patient fatigue reported before the initiation of cancer treatment appears to be associated with an increased risk of subsequent treatment-related adverse events, according to new research.